BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Bampidirsen readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Bampidirsen\, from ClinicalTrials.gov est
 imates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07209332-10847@assetmemo.bio
DTSTAMP:20261121T004049Z
DTSTART;VALUE=DATE:20290331
DTEND;VALUE=DATE:20290401
SUMMARY:Bampidirsen: Phase 2 readout est. (NCT07209332)
DESCRIPTION:Bampidirsen\, phase 2\, Duchenne Muscular Dystrophy.\nStudy: Op
 en-Label Extension Study of WVE-N531 in Patients With Duchenne Muscular Dy
 strophy\nEstimated primary completion: March 2029. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/bampidirsen#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT07209332
URL:https://assetmemo.bio/drug/bampidirsen#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
